These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 20651984

  • 21. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
    Ling SC, Lau EK, Al-Shabeeb A, Nikolic A, Catalano A, Iland H, Horvath N, Ho PJ, Harrison S, Fleming S, Joshua DE, Allen JD.
    Haematologica; 2012 Jan; 97(1):64-72. PubMed ID: 21993678
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells.
    Periyasamy-Thandavan S, Jackson WH, Samaddar JS, Erickson B, Barrett JR, Raney L, Gopal E, Ganapathy V, Hill WD, Bhalla KN, Schoenlein PV.
    Autophagy; 2010 Jan; 6(1):19-35. PubMed ID: 20110775
    [Abstract] [Full Text] [Related]

  • 24. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, Jäck HM, Voll RE.
    Cancer Res; 2007 Feb 15; 67(4):1783-92. PubMed ID: 17308121
    [Abstract] [Full Text] [Related]

  • 25. Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.
    Zhen YZ, Lin YJ, Liu XJ, Shang BY, Zhen YS.
    Anticancer Drugs; 2013 Jul 15; 24(6):609-16. PubMed ID: 23698252
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 28. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
    Dasmahapatra G, Patel H, Dent P, Fisher RI, Friedberg J, Grant S.
    Br J Haematol; 2013 Apr 01; 161(1):43-56. PubMed ID: 23360303
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
    Huang H, Liu N, Yang C, Liao S, Guo H, Zhao K, Li X, Liu S, Guan L, Liu C, Xu L, Zhang C, Song W, Li B, Tang P, Dou QP, Liu J.
    PLoS One; 2012 Apr 01; 7(12):e52576. PubMed ID: 23285100
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
    Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, Catley L, Mitsiades C, Munshi N, Tai YT, Suh N, Gribble GW, Honda T, Schlossman R, Richardson P, Sporn MB, Anderson KC.
    Blood; 2004 Apr 15; 103(8):3158-66. PubMed ID: 15070698
    [Abstract] [Full Text] [Related]

  • 33. Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo.
    Escalante AM, McGrath RT, Karolak MR, Dorr RT, Lynch RM, Landowski TH.
    Cancer Chemother Pharmacol; 2013 Jun 15; 71(6):1567-76. PubMed ID: 23572175
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model.
    Siveen KS, Mustafa N, Li F, Kannaiyan R, Ahn KS, Kumar AP, Chng WJ, Sethi G.
    Oncotarget; 2014 Feb 15; 5(3):634-48. PubMed ID: 24504138
    [Abstract] [Full Text] [Related]

  • 37. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
    Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, Rangwala R, Piao S, Chang YC, Scott EC, Paul TM, Nichols CW, Porter DL, Kaplan J, Mallon G, Bradner JE, Amaravadi RK.
    Autophagy; 2014 Aug 15; 10(8):1380-90. PubMed ID: 24991834
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.